Lin, Richard J. http://orcid.org/0000-0002-0834-7880
Baser, Raymond E.
Elko, Theresa A.
Korc-Grodzicki, Beatriz
Shahrokni, Armin
Maloy, Molly A.
Young, James W.
Tamari, Roni
Shah, Gunjan L.
Shaffer, Brian C.
Scordo, Michael
Sauter, Craig S.
Ponce, Doris M.
Politikos, Ioannis
Perales, Miguel-Angel
Papadopoulos, Esperanza B.
Gyurkocza, Boglarka
Dahi, Parastoo B.
Cho, Christina
Barker, Juliet N.
Tomas, Ana Alarcón
Flores, Nerea Castillo
Sanchez-Escamilla, Míriam
Segundo, Lucrecia Yáñez San
Jakubowski, Ann A.
Giralt, Sergio A.
Article History
Received: 27 April 2020
Revised: 23 June 2020
Accepted: 14 July 2020
First Online: 21 July 2020
Compliance with ethical standards
:
: SAG<b>—</b>Advisory Board for Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz Pharmaceuticals, Takeda, Novartis, Kite, Spectrum Pharma; Research funding from Amgen, Actinuum, Celgene, Johnson & Johnson, Miltenyi, Takeda. CSS<b>—</b>Consultant on advisory boards for: Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Precision Biosciences. Kite—a Gilead Company and GSK: GlaxoSmithKline. Research funds for investigator-initiated trials from: Juno Therapeutics and Sanofi-Genzyme. GLS—Research funding from Janssen and Amgen. MS—Consultancy and research funding: Angiocrine Bioscience; Consultancy: McKinsey & Company; Consultancy on Advisory Boards for: Omeros Corporation and Kite—A Gilead Company. JNB—Research funding: Angiocrine Bioscience and Merck. PBD<b>—</b>Advisory board of Kite (Gilead). IP—Research funding: Merck; DSMB member: ExCellThera. MAP<b>—</b>Honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. Research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi Biotec. The remaining authors declare no conflict of interest.